Literature DB >> 1810443

Interleukin 6 and cancer treatment.

O Martínez-Maza1, J S Berek.   

Abstract

Interleukin 6 (IL-6) is a pleiotropic cytokine, with a wide range of biological effects. The diverse biological actions of IL-6 could play important roles in the enhancement or suppression of tumor growth and development. IL-6 has been seen to act as an autocrine and/or paracrine growth factor for various human tumors, including multiple myeloma, renal cancer, and AIDS-associated Kaposi's sarcoma. However, IL-6 also can exert potent anti-tumor effects: administration of IL-6 has been seen to result in decreased tumor appearance in experimental animal systems. Therefore, potentially useful anti-tumor therapeutic strategies could include the inhibition of the activity of IL-6, or alternatively, the enhancement of anti-tumor responses by the administration of exogenous IL-6.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1810443

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  3 in total

1.  Calcineurin activates interleukin-6 transcription in mouse skeletal muscle in vivo and in C2C12 myotubes in vitro.

Authors:  David L Allen; Jill J Uyenishi; Allison S Cleary; Ryan S Mehan; Sarah F Lindsay; Jason M Reed
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-11-11       Impact factor: 3.619

2.  First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.

Authors:  Muhammad Wasif Saif; Jia Li; Lynne Lamb; Kristin Kaley; Kyle Elligers; Zaoli Jiang; Scott Bussom; Shwu-Huey Liu; Yung-Chi Cheng
Journal:  Cancer Chemother Pharmacol       Date:  2013-12-03       Impact factor: 3.333

3.  The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways.

Authors:  D B Badgwell; Z Lu; K Le; F Gao; M Yang; G K Suh; J-J Bao; P Das; M Andreeff; W Chen; Y Yu; A A Ahmed; W S-L Liao; R C Bast
Journal:  Oncogene       Date:  2011-06-06       Impact factor: 9.867

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.